Upcoming Webinars


Biosimilars: Market Access Challenges & Opportunities Worldwide
February 2, 2021
10:00AM EST | 3:00PM GMT | 4:00PM CET
 

Most Recent


Shaking the Myth of Real World Evidence: Updates From the RWE Transparency Initiative

Dec 2020

This session will provide updates from the initiative including progress on the study registration site and the special task force on RWE protocol templates.

The 4th Industrial Revolution, Digital Transformation and Patient Centricity: A Leadership View

Dec 2020

In this presentation we will explore what the 4th Industrial Revolution is, how it impacts on the progressive movement towards digital transformation in our workplace. We will show that there is an inevitable convergence between the health ecosystem and the digital world.

CHEERS II: Bold Directions for New Reporting Standards?

Dec 2020

This webinar will discuss the rationale for the revision of the original Consolidated Health Economic Evaluation Reporting Standards (CHEERS) reporting guidelines and outline directions for the new reporting standards, as suggested by a Delphi survey.

The Proper Order of Things is Often a Mystery: A Novel Approach to Selecting Treatment Sequences

Dec 2020

In this webinar, we will consider the apparent disconnect between HTA assessments of treatments within a specified location in a treatment sequence and clinical practice where a treatment sequence is tailored to the patient.

Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs

Dec 2020

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.

Using Patient Preferences to Inform Decision Making

Nov 2020

The current regulatory and assessor landscape will be discussed including the European Union’s Innovative Medicines Initiative (IMI) and the Medical Device Innovation Consortium (MDIC). The task force is presenting their work to date with the request for feedback.

Economic Evaluation



CHEERS II: Bold Directions for New Reporting Standards?

Dec 2020

This webinar will discuss the rationale for the revision of the original Consolidated Health Economic Evaluation Reporting Standards (CHEERS) reporting guidelines and outline directions for the new reporting standards, as suggested by a Delphi survey.

Open Source Models in HEOR: Benefits, Challenges, and ISPOR Members’ Perceptions

Sep 2020

There is growing interest in the use of open source models (OSMs) for cost-effectiveness analysis. In this session, the leaders of a new Special Interest Group (SIG) will introduce the general ISPOR membership to OSMs, providing an overview of some of the perceived benefits and potential barriers to their adoption. The presenters will share the findings of a recent survey, relaying ISPOR members’ experiences and expectations about OSMs. The webinar will be used to help shape the direction of future events and the focus of the SIG.

Financing Epidemics: Developing an Insurance Scheme for Outbreaks in Africa

Apr 2020

This timely webinar will highlight an initiative under development to create an insurance scheme in African countries to provide emergency financing for disease outbreaks. Country-level engagement to tailor the scheme to country needs and costing of outbreak responses to inform estimates of premiums will be specifically addressed.

Top 10 Trends in Health Economics and Outcomes Research 2020

Apr 2020

ISPOR—the professional society for health economics and outcomes research (HEOR), announced the publication of its 2020 Top 10 HEOR Trends report early this year. In the report, the Society has identified the top 10 HEOR trends that will shape the field and influence healthcare over 2020 and the near future.


Health Technology Assessment



Global Experiences with the Use of HTA for Health Benefit Packages Development

Aug 2020

In this session, experts from Latin America, Asia-Pacific and EMEA will discuss the role of HTA in UHC, including priority setting, coverage and financing, and share their experience in effective application of HTA to support designing benefits package for UHC while tackling the encountered challenges.

New Developments in Health Technology Assessment in Asia Pacific

Apr 2020

Health technology assessment (HTA) is gaining widespread acceptance and plays a vital role in healthcare decision making in many countries across the Asia Pacific region. In order to meet the changing demands of patients in light of new health technology innovations, HTA processes have needed to adapt. In this webinar, leading HTA experts from Thailand and South Korea will provide updates on recent developments in their countries’ HTA processes to strengthen patient access to innovative health technologies.


Real-World Data & Information Systems


Shaking the Myth of Real World Evidence: Updates From the RWE Transparency Initiative

Dec 2020

This session will provide updates from the initiative including progress on the study registration site and the special task force on RWE protocol templates.

French Administrative Health Care Database (SNDS): Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU

Sep 2020

Certara’s extensive experience with the recently accessible French administrative healthcare database (SNDS) has provided key insights into how the database can be used for a larger impact on patient access, health technology and public health assessments

The Usage of Real-World Evidence (RWE): Monitoring and Managing Health Technologies In Latin America - Where We Are and Where We Are Heading

Aug 2020

In this webinar, a holistic multi-stakeholder discussion about the stage of RWE and how its use could improve the performance of healthcare systems in LATAM, including priority setting, health technology assessment (HTA), effectiveness and safety measurement, and innovative access models.


Patient-Centered Research



The 4th Industrial Revolution, Digital Transformation and Patient Centricity: A Leadership View

Dec 2020

In this presentation we will explore what the 4th Industrial Revolution is, how it impacts on the progressive movement towards digital transformation in our workplace. We will show that there is an inevitable convergence between the health ecosystem and the digital world.

Using Patient Preferences to Inform Decision Making

Nov 2020

The current regulatory and assessor landscape will be discussed including the European Union’s Innovative Medicines Initiative (IMI) and the Medical Device Innovation Consortium (MDIC). The task force is presenting their work to date with the request for feedback.

Patient-Reported Outcomes Webinar 2 (3 Part Series): Generating PRO Data – and Using It

Oct 2020

To advocate for a meaningful use of PROs to best reflect patient reality, patient advocates need to understand what PROs are, how PROs are being measured, and how they can bring the patient perspective into development, use and reporting of PRO measurements. This information will be presented across a 3-part webinar series

Patient Reported Outcomes Webinar 3: Developing New Patient-Reported Outcomes Instruments

Oct 2020

To advocate for a meaningful use of PROs to best reflect patient reality, patient advocates need to understand what PROs are, how PROs are being measured, and how they can bring the patient perspective into development, use and reporting of PRO measurements. This information will be presented across a 3-part webinar series outlined below.

Methodical & Statistical Research



The Proper Order of Things is Often a Mystery: A Novel Approach to Selecting Treatment Sequences

Dec 2020

In this webinar, we will consider the apparent disconnect between HTA assessments of treatments within a specified location in a treatment sequence and clinical practice where a treatment sequence is tailored to the patient.

Health Policy & Regulatory



Biosimilars: Unleashing The Potential For Improved Patient Access And Cost Savings In The United States

Oct 2020

The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.

Study Approaches


Methods Maze: Pointers for Selecting Survival Extrapolation Models for Cancer Immunotherapy

Oct 2020

In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.

Why and How to Use Qualitative Research Methods in Conjunction with Discrete Choice Experiments in Health Care

Jun 2020

This webinar will explore why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare. Speakers will discuss formative qualitative research for the identification and generation of attributes and levels and qualitative research for testing survey comprehension and decision-making processes.

Adding Depth to Observational Research through Data Linkage

Apr 2020

This webinar will explore the value and challenges of linking administrative claims data to additional data sources in order to provide a more comprehensive look at the patient journey through a disease state. Data linkage types, techniques and best practices will be discussed.


Epidemiology & Public Health


ISPOR/IVI COVID Webinar #5: Using VA/HTA in Pursuing Innovation and Access in a Pandemic

Nov 2020

This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve the scientific credibility and relevance of VA/HTA to pandemic preparedness.

ISPOR/IVI COVID Webinar #4: The Role of Public Health – How can VA/HTA Inform Pandemic Policy Interventions and Public Resource Allocation?

Nov 2020

COVID-19 has brought home the importance of public health expertise and investment. How should VA/HTA address risks and benefits of public health policy interventions? How do we model the interactions between health and other sectors in our economy? What are the roles of the public vs. private sector in public health infrastructure and interventions? Are there policy implications for public health investment that VA/HTA can help frame?

ONE HEALTH Perspectives on HEOR

Oct 2020

This webinar features a range of international speakers who will introduce several One Health-related topics as they pertain to HEOR, with a view gauging interest in the formation of an ISPOR Animal and One Health Special Interest Group (SIG).

Balancing Economics and Ethics: How Can VA/HTA Support Equitable Resource Allocation?

Sep 2020

Evolving data from COVID-19 tell the story we already know: the impact of this disease affects people – especially people of color - disproportionately, both in terms of risk and prevalence, as well as access to care and outcomes. In considering VA/HTA approaches, as well as in discerning how to apply such findings, how must we address questions of ethics and equity?


Specific Diseases & Conditions


Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs

Dec 2020

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.

Value Assessment in Alzheimer's Disease: A Focus on Equity

Nov 2020

This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.

Valuing Future Alzheimer’s Disease Medicines: Extending the Paradigm

Oct 2020

This webinar seeks to explore some of these broader elements within the context of evolving value assessment and considers how they may meaningfully be incorporated to facilitate a more holistic approach to valuing medical innovation.

Need More Information or Have Questions?

Contact us for more information on ISPOR education and training.

Contact Us

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×